# EDGAR Filing Document

**Accession Number:** 0001642159
**File Stem:** 0001641172-25-024303
**Filing Date:** 2025-8
**Character Count:** 110656
**Document Hash:** 94f1f592dec2495b7595ef97faacb91d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024303.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001641172-25-024303

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sigyn Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001642159
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472573116
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55575
- **FILM NUMBER:** 251223116

**BUSINESS ADDRESS:**
- **STREET 1:** 9190 W OLYMPIC BLVD # 263
- **CITY:** BEVERLY HILLS
- **STATE:** CA
- **ZIP:** 90212
- **BUSINESS PHONE:** 619-368-2000

**MAIL ADDRESS:**
- **STREET 1:** 9190 W OLYMPIC BLVD # 263
- **CITY:** BEVERLY HILLS
- **STATE:** CA
- **ZIP:** 90212

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reign Resources Corp
- **DATE OF NAME CHANGE:** 20200512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reign Sapphire Corp
- **DATE OF NAME CHANGE:** 20150512

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): August 14, 2025 (August 7, 2025)

**SIGYN THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-55575** | **84-4210559** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| 2305 Historic Decatur Road |  |
| Suite 100 |  |
| San Diego, California | 92106 |
| (Address of principal executive offices) | (Zip Code) |

---

**Registrant's telephone number, including area code:** 619.353.0800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**ITEM 1.01 Entry into a Material Definitive Agreement** 

On August 8, 2025, Sigyn Therapeutics, Inc. (the "Company") entered into a Convertible Note Purchase Agreement (the "Purchase Agreement") with Lambda Venture Partners, LLC, pursuant to which the Company may issue and sell, subject to the terms of the Purchase Agreement, up to $550,000 in aggregate principal amount of one-year 8% convertible promissory notes (the "Notes") in exchange for $500,000. The Notes are convertible, at the option of the holder, into shares of the Company's common stock at a conversion price equal to a 35% discount to the lowest traded price of the Company's common shares during the ten (10) trading days immediately prior to the date on the notice of conversion. The issuances of the foregoing securities are exempt from registration pursuant to Section 4(a)(2) of the Securities Act promulgated thereunder as the Sellers are sophisticated investors and familiar with the Company's operations. No stock purchase warrants were issued as part of the agreement.

On August 11, 2025, the Company issued the first tranche of Notes in the aggregate principal amount of $110,000 to Lambda Venture Partners, LLC, and received $100,000 in proceeds, consistent with the Purchase Agreement.

The foregoing description of the Purchase Agreement and the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, the Form of Convertible Note, and any related documentation, copies of which will be filed as exhibits to the Current Report on Form 8-K and are incorporated herein by reference.

**Item 3.02 Unregistered Sale of Securities**.

See Item 1.01.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**.

On August 8, 2025, Richa Nand and Michael Ryan notified Sigyn Therapeutics, Inc. (the "Company") of their decision to resign from the Company's Board of Directors, effective August 8, 2025. On August 7, 2025, Christopher Wetzel notified the Company of his decision to resign from the Board of Directors, effective August 7, 2025. The resignations were based on the Company's discontinuation of directors' and officers' liability insurance coverage, as further described below.

The Company has provided Ms. Nand, Mr. Ryan and Mr. Wetzel with a copy of this Form 8-K and the disclosures made herein. Should the Company receive a letter from Ms. Nand, Mr. Ryan or Mr. Wetzel that does not agree with the disclosure made herein, the Company will file an amendment to this Form 8-K within two business days after the receipt of such letter.

**Item 8.01 Other Events.** 

The Company's directors' and officers' liability insurance policy expired on August 4, 2025. The Company did not extend the policy and has not yet obtained replacement coverage. The Company is evaluating alternatives for securing such coverage in the future. The discontinuation of coverage was not related to any specific claim or proceeding against the Company or its directors or officers.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Title** |
| 99.1 | [Convertible Note Purchase Agreement](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SIGYN THERAPEUTICS, INC.** | **SIGYN THERAPEUTICS, INC.** |
| Date: August 14, 2025 | By: | */s/ James A. Joyce* |
|  |  | James A. Joyce, Chairman and CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

**NOTE PURCHASE AGREEMENT**

**THIS NOTE PURCHASE AGREEMENT** (this "<u>Agreement</u>"), dated as of August 8, 2025, (the "<u>Execution Date</u>"), is entered into by and between **SIGYN THERAPEUTICS, INC.**, a Delaware corporation (the "<u>Company</u>"), and **LAMBDA VENTURE PARTNERS, LLC**, a Florida limited liability company (the "<u>Buyer</u>"). Each capitalized term used herein shall have the meaning ascribed thereto in <u>Section 10</u> below or as otherwise defined herein.

**WHEREAS**, the Company and the Buyer are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the "<u>SEC</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"); and

**WHEREAS**, the Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a series of a convertible promissory note of the Company, in the form attached hereto as <u>Exhibit A</u> in an aggregate face amount of $550, 0000 with the initial funding tranche being in the amount of $103,500 as more set forth on the <u>Issuance Schedule</u> attached hereto (such note, together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, a "<u>Note</u>"), convertible into shares (the "<u>Conversion Shares</u>") of common stock, $0.001 par value per share, of the Company (the "<u>Common Stock</u>") pursuant to the terms of the Note; such amounts set forth on the Issuance Schedule (the Note and, the Conversion Shares, are collectively referred to as the "<u>Securities</u>"; and

**NOW THEREFORE**, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Buyer hereby agree as follows:

1. <u>PURCHASE AND SALE OF SECURITIES.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Closing</u>.
 On the Closing Date (as defined below), the Company shall sell and issue to the Buyer and
 the Buyer shall purchase and fund a Note in such principal amount, and for such funding price,
 set forth on the <u>Issuance Schedule</u> under (the " <u>Closing</u> "), which
 such initial funding amount shall be $103,500.00 for the Closing (the " <u>Company Funding Amount</u> " less legal fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Closing Date</u>. Subject to the satisfaction (or written waiver) of the conditions set forth in <u>Section 7</u> and <u>Section 8</u> below, the date of the issuance and sale of the Note
 constituting the Closing pursuant to this Agreement (the " <u>Closing Date</u> ")
 shall be the Execution Date. Subsequent closings shall occur at a time and place agreed by
 the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Form of Payment</u>. On the Closing Date, the Buyer shall deliver the Company Funding Amount by
 wire transfer of immediately available funds, in accordance with the Company's written
 wiring instructions.

2. <u>REPRESENTATIONS AND WARRANTIES OF THE BUYER</u>. The Buyer represents and warrants to the Company that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Investment Purpose</u>. As of the Execution Date, the Buyer is purchasing the Securities for its own
 account for investment only and not with a view towards the public sale or distribution thereof,
 except pursuant to sales registered or exempted from registration under the Securities Act; <u>provided</u>, <u>however</u>, that by making the foregoing representation and warranty,
 the Buyer does not agree to hold any of the Securities for any minimum or other specific
 term and reserves the right to dispose of all or any portion of the Securities at any time
 in accordance with or pursuant to a registration statement or an exemption under the Securities
 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Reliance on Exemptions</u>. The Buyer understands that the Securities are being offered and sold to
 it in reliance upon specific exemptions from the registration requirements of United States
 federal and state securities laws and that the Company is relying upon the truth and accuracy
 of, and the Buyer's compliance with, the representations, warranties, agreements, acknowledgments
 and understandings of the Buyer set forth herein in order to determine the availability of
 such exemptions and the eligibility of the Buyer to acquire the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Information</u>.
 The Buyer and its advisors, if any, have been furnished with all materials relating to the
 business, finances and operations of the Company and materials relating to the offer and
 sale of the Securities which have been requested by the Buyer or its advisors. The Buyer
 and its advisors, if any, have been afforded the opportunity to ask questions of the Company.
 Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material non-public
 information and will not disclose such information unless such information is disclosed to
 the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries
 nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives
 shall modify, amend or affect Buyer's right to rely on the Company's representations
 and warranties contained in <u>Section 3</u> below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Authorization; Enforcement; Organization</u>. This Agreement has been duly and validly authorized by the
 Buyer. This Agreement has been duly executed and delivered on behalf of the Buyer, and this
 Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance
 with its terms. The Buyer is a limited liability company organized under the laws of the
 State of Wyoming.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Accredited Investor Status</u>. The Buyer is (i) an "accredited investor" as that term is
 defined in Rule 501 of the General Rules and Regulations under the Securities Act by reason
 of Rule 501(a)(3) (an " <u>Accredited Investor</u> "), (ii) experienced in making
 investments of the kind described in this Agreement and the related documents, (iii) able,
 by reason of the business and financial experience of its officers (if an entity) and professional
 advisors (who are not affiliated with or compensated in any way by the Company or any of
 its Affiliates or selling agents), to protect its own interests in connection with the transactions
 described in this Agreement, and the related documents, and (iv) able to afford the entire
 loss of its investment in the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>General Solicitation</u>. The Buyer is not purchasing the Securities as a result of any advertisement,
 article, notice or other communication regarding the Securities published in any newspaper,
 magazine or similar media or broadcast over television or radio or presented at any seminar
 or any other general solicitation or general advertisement.

3. <u>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</u>. The Company represents and warrants to the Buyer that
 as of the Execution Date and as of the Closing Date (or as of such other time expressly specified
 below):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Corporate Governance Compliance</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Issuance of Note and Conversion Shares</u>. The Conversion Shares have been duly authorized and fully
 reserved for issuance and, upon conversion of the Note in accordance with its terms, will
 be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims
 and encumbrances with respect to the issue thereof, with the holders being entitled to all
 rights accorded to a holder of Common Stock. The Conversion Shares shall not be subject to
 pre-emptive rights or other similar rights of stockholders of the Company (except to the
 extent already waived) and will not impose personal liability upon the holder thereof, other
 than restrictions on transfer provided for in the Transaction Documents and under the Securities
 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Organization and Qualification</u>. The Company is a corporation duly incorporated, validly existing and
 in good standing under the laws of the State of Delaware, with the requisite corporate power
 and authority to own and use its properties and assets and to carry on its business as currently
 conducted. Each of the Subsidiaries is an entity duly incorporated or otherwise organized,
 validly existing and in good standing under the laws of the jurisdiction of its incorporation
 or organization, with the requisite corporate power and authority to own and use its properties
 and assets and to carry on its business as currently conducted. Each of the Company and the
 Subsidiaries is not in violation or default of any of the provisions of its respective certificate
 or articles of incorporation, bylaws or other organizational or charter documents. Each of
 the Company and the Subsidiaries is duly qualified to conduct business and is in good standing
 as a foreign corporation or other entity in each jurisdiction in which the nature of the
 business conducted or property owned by it makes such qualification necessary, except where
 the failure to be so qualified or in good standing, as the case may be, could not have or
 reasonably be expected to result in a Material Adverse Effect and no proceeding has been
 instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
 limit or curtail such power and authority or qualification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into
 and perform its obligations under this Agreement and the other Transaction Documents. The
 execution and delivery of this Agreement and the other Transaction Documents by the Company
 and the consummation by it of the transactions contemplated hereby and thereby have been
 duly authorized by all necessary corporate action, and no further consent or authorization
 of the Company or its Board of Directors or stockholders is required. Each of this Agreement
 and the other Transaction Documents has been duly executed and delivered by the Company and
 constitutes a valid and binding obligation of the Company enforceable against the Company
 in accordance with its terms, except as such enforceability may be limited by applicable
 bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement
 of, creditors' rights and remedies or by other equitable principles of general application.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Capitalization</u>.
 As of the Execution Date, the authorized capital stock of the Company is as set forth in
 the SEC Documents (as defined below). Except as set forth on <u>Schedule 3(a)(iv)</u>, the
 Company has not issued any capital stock since its most recently filed SEC Document, other
 than pursuant to the exercise of employee stock options under the Company's stock option
 plans, the issuance of shares of Common Stock to employees pursuant to the Company's
 employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock
 Equivalents outstanding as of the date of the most recently filed SEC Document. Except as
 disclosed in the SEC Documents, no shares are reserved for issuance pursuant to the Company's
 stock option plans, no shares are reserved for issuance pursuant to the terms of any Common
 Stock Equivalents (other than the Note) exercisable for, or convertible into or exchangeable
 for shares of Common Stock and sufficient shares are reserved for issuance upon conversion
 of the Note (as required by the Note and Transfer Agent Instruction Letter). All of such
 outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly
 issued, fully paid and non-assessable. No shares of capital stock of the Company are subject
 to preemptive rights or any other similar rights of the stockholders of the Company or any
 liens or encumbrances imposed through the actions or failure to act of the Company. Except
 as disclosed in the SEC Documents, as of the Execution Date, (i) there are no outstanding
 options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal,
 agreements, understandings, claims or other commitments or rights of any character whatsoever
 relating to, or securities or rights convertible into or exchangeable for any shares of capital
 stock of the Company or any of its Subsidiaries, or arrangements by which the Company or
 any of its Subsidiaries is or may become bound to issue additional shares of capital stock
 of the Company or any of its Subsidiaries, (ii) there are no agreements or arrangements under
 which the Company or any of its Subsidiaries is obligated to register the sale of any of
 its or their securities under the Securities Act and (iii) there are no anti-dilution or
 price adjustment provisions contained in any security issued by the Company (or in any agreement
 providing rights to security holders) that will be triggered by the issuance of the Securities.
 The Company has filed in its SEC Documents true and correct copies of the Company's
 Certificate of Incorporation as in effect on the Execution Date, the Company's bylaws,
 as in effect on the Execution Date, and the terms of all securities convertible into or exercisable
 for Common Stock of the Company and the material rights of the holders thereof in respect
 thereto. The Company shall provide the Buyer a certification of this representation signed
 by the Company's Chief Executive Officer on behalf of the Company as of the Closing
 Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>No Conflicts</u>. The execution, delivery and performance of this Agreement and the other Transaction
 Documents by the Company and the consummation by the Company of the transactions contemplated
 hereby and thereby (including, without limitation, the issuance and reservation for issuance
 of the Conversion Shares) will not (a) result in a violation of the Company's or any
 Subsidiary's certificate or articles of incorporation, by-laws or other organizational
 or charter documents, (b) conflict with, or constitute a material default (or an event that
 with notice or lapse of time or both would become a material default) under, result in the
 creation of any Lien upon any of the properties or assets of the Company or any Subsidiary,
 or give to others any rights of termination, amendment, acceleration or cancellation of,
 any agreement, indenture, instrument or any "lock-up" or similar provision of
 any underwriting or similar agreement to which the Company or any Subsidiary is a party,
 or (c) result in a violation of any federal, state or local law, rule, regulation, order,
 judgment or decree (including federal and state securities laws and regulations) applicable
 to the Company or any Subsidiary or by which any property or asset of the Company or any
 Subsidiary is bound or affected (except for such conflicts, defaults, terminations, amendments,
 accelerations, cancellations and violations as would not, individually or in the aggregate,
 have a Material Adverse Effect), nor is the Company otherwise in violation of, conflict with
 or in default under any of the foregoing. The business of the Company is not being conducted
 in violation of any law, ordinance or regulation of any governmental entity, except for possible
 violations that either singly or in the aggregate do not and will not have a Material Adverse
 Effect. The Company is not required under federal, state or local law, rule or regulation
 to obtain any consent, authorization or order of, or make any filing or registration with,
 any court or governmental agency in order for it to issue the Conversion Shares or to execute,
 deliver or perform any of its obligations under this Agreement or the other Transaction Documents
 (other than any SEC, FINRA or state securities filings that may be required to be made by
 the Company subsequent to Closing).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>SEC and Offering Compliance</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>SEC Documents</u>. The Company has filed all reports, schedules, forms, statements and other
 documents required to be filed by the Company under the Securities Act and the Exchange Act
 for the Company to be deemed fully "fully reporting" and "current"
 and in compliance with the periodic and current reporting requirements of Section 13 or 15(d)
 of the Exchange Act, and in compliance with the Rule 144(c)(1) under the Securities Act (the
 foregoing materials, including the exhibits thereto and documents incorporated by reference
 therein, being collectively referred to herein as the " <u>SEC Documents</u> ").
 The SEC Documents comply in all material respects with the requirements of the Securities
 Act and the Exchange Act, as applicable, and other federal laws, rules and regulations applicable
 to such SEC Documents, and none of the SEC Documents contain any untrue statement of a material
 fact or omit to state a material fact required to be stated therein or necessary in order
 to make the statements therein, in light of the circumstances under which they were made,
 not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Financial Statements</u>. The financial statements of the Company included in its OTC Filings and Disclosures
 and SEC Documents (the " <u>Financial Statements</u> ") comply as to form and substance
 in all material respects with applicable accounting requirements and the published rules
 and regulations of the SEC as well as other applicable rules and regulations with respect
 thereto. Such Financial Statements have been prepared in accordance with generally accepted
 accounting principles applied on a consistent basis during the periods involved (except (a)
 as may be otherwise indicated in such Financial Statements or the notes thereto or (b) in
 the case of unaudited interim statements, to the extent they may not include footnotes or
 may be condensed or summary statements) and fairly present in all material respects the financial
 position of the Company as of the dates thereof and the results of operations and cash flows
 for the periods then ended (subject, in the case of unaudited statements, to normal, immaterial,
 year-end audit adjustments). The Company maintains a system of internal accounting controls
 appropriate for its size. There is no transaction, arrangement, or other relationship between
 the Company and an unconsolidated or other off balance sheet entity that is not disclosed
 by the Company in its Financial Statements or otherwise that would be reasonably likely to
 have a Material Adverse Effect. Except with respect to the material terms and conditions
 of the transactions contemplated by the Transaction Documents, the Company confirms that
 neither it nor any other Person acting on its behalf has provided the Buyer or its agents
 or counsel with any information that it believes constitutes or might constitute material,
 non-public information. The Company understands and confirms that the Buyer will rely on
 the foregoing representation in effecting transactions in securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Acknowledgment Regarding Buyer's Purchase of Securities</u>. The Company acknowledges and agrees that
 the Buyer is acting solely in the capacity of an arm's length purchaser with respect
 to the Transaction Documents and the transactions contemplated hereby and thereby and that
 the Buyer is neither (i) an officer or director of the Company or any of its Subsidiaries,
 nor (ii) an "affiliate" (as defined in Rule 144) of the Company or any of its
 Subsidiaries. The Company further acknowledges that the Buyer is not acting as a financial
 advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity)
 with respect to the Transaction Documents and the transactions contemplated hereby and thereby,
 and any advice given by a Buyer or any of its representatives or agents in connection with
 the Transaction Documents and the transactions contemplated hereby and thereby is merely
 incidental to the Buyer's purchase of the Securities. The Company further represents
 to the Buyer that the Company's decision to enter into the Transaction Documents has
 been based solely on the independent evaluation by the Company and its representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>No Integrated Offering</u>. Neither the Company, nor any person acting on its or their behalf,
 has directly or indirectly made any offers or sales in any security or solicited any offers
 to buy any security under circumstances that would require registration under the Securities
 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the
 Buyer will not be integrated with any other issuance of the Company's securities (past,
 current or future) for purposes of any stockholder approval provisions applicable to the
 Company or its securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Brokers.</u> No broker is entitled to a commission payable by the Company in connection with the transactions
 contemplated by this transaction and the Company has taken no action which would give rise
 to any claim by any person for brokerage commissions, transaction fees or similar payments
 relating to this Agreement, or the transactions contemplated hereby. Any all fees due to
 any brokers shall be paid and satisfied by the Company at the Closing except as otherwise
 provided in <u>Section 1(c)</u> of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Disclosure.</u> All information relating to or concerning the Company or any of its Subsidiaries set forth
 in this Agreement and provided to the Buyer pursuant in connection with the transactions
 contemplated hereby is true and correct in all material respects and the Company has not
 omitted to state any material fact necessary in order to make the statements made herein
 or therein, in light of the circumstances under which they were made, not misleading. No
 event or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries
 or its or their business, properties, prospects, operations or financial conditions, which,
 under applicable law, rule or regulation, requires public disclosure or announcement by the
 Company but which has not been so publicly announced or disclosed (assuming for this purpose
 that the Company's reports filed under the Exchange Act are being incorporated into
 an effective registration statement filed by the Company under the Securities Act).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <u>Shell Company Status</u>. The Company is not currently an issuer identified in Rule 144(i)(1)(i)
 under the Securities Act, and, if it was at any time previously been such an issuer, then
 the Company is subject to the reporting requirements of Section 13 or 15(d) of the Exchange
 Act, has filed all reports and other materials required to be filed by Section 13 or 15(d)
 of the Exchange Act, as applicable during the preceding 12 months, and, as of a date at least
 one year prior to the Execution Date, has filed current "Form 10 information"
 with the SEC (as defined in Rule 144(i)(3) of the Securities Act) reflecting its status as
 an entity that is no longer an issuer described in Rule 144(i)(1)(i) of the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) <u>No Disqualification Events</u>. With respect to Securities to be offered and sold hereunder
 in reliance on Rule 506 under the Securities Act (" <u>Regulation D Securities</u> "),
 none of the Company, any of its predecessors, any affiliated issuer, any director, executive
 officer, other officer of the Company participating in the offering hereunder, any beneficial
 owner of 20% or more of the Company's outstanding voting equity securities, calculated
 on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
 the Securities Act) connected with the Company in any capacity at the time of sale (each,
 an " <u>Issuer Covered Person</u> " and, together, " <u>Issuer Covered Persons</u> ")
 is subject to any of the "bad actor" disqualifying events described in Rule 506(d)(1)(i)(viii)
 under the Securities Act (each, a " <u>Disqualification Event</u> "), except for
 a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
 care to determine whether any Issuer Covered Person is subject to a Disqualification Event.
 The Company has complied, to the extent applicable, with its disclosure obligations under
 Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) <u>Other Covered Persons</u>. The Company is not aware of any Person (other than any Issuer Covered
 Person) that has been or will be paid (directly or indirectly) remuneration for solicitation
 of buyers or potential purchasers in connection with the sale of any Regulation D Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>No General Solicitation; Placement Agent</u>. Neither the Company, nor any of its Subsidiaries
 or Affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
 solicitation or general advertising (within the meaning of Regulation D) in connection with
 the offer or sale of the Securities. Neither the Company nor any of its Subsidiaries has
 engaged any placement agent in connection with the sale of the Securities. In the event that
 a broker-dealer or other agent or advisory is engaged by the Company subsequent to the initial
 Closing, the Company shall be responsible for the payment of any placement agent's
 fees, financial advisory fees, or brokers' commissions (other than for persons engaged
 by any Buyer or its investment advisor) relating to or arising out of the transactions contemplated
 hereby in connection with the sale of the Securities. The Company shall pay, and hold the
 Buyer harmless against, any liability, loss or expense (including, without limitation, attorney's
 fees and out-of-pocket expenses) arising in connection with any such claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) <u>Investment Company Status</u>. The Company is not, and upon consummation of the sale of the Securities
 will not be, an "investment company," a company controlled by an "investment
 company" or an "affiliated person" of, or "promoter" or "principal
 underwriter" for, an "investment company" as such terms are defined in
 the Investment Company Act of 1940, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) <u>Transfer Taxes</u>. On the Closing Date, all stock transfer or other taxes (other than income or similar
 taxes) which are required to be paid in connection with the sale and transfer of the Securities
 to be sold to the Buyer hereunder will be, or will have been, fully paid or provided for
 by the Company, and all laws imposing such taxes will be or will have been complied with.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) <u>Compliance with Rule 15c2-11</u>. On the Closing Date, and at all times that any of the Securities remain
 outstanding, the Company shall maintain as publicly available all information required by
 paragraph (b) of Rule 15c2-11 of the Exchange Act (as effective on September 26, 2021), as
 amended, such that brokers or dealers attempting to publish any quotation for the Common
 Stock or, directly or indirectly, to submit any such quotation for publication, shall be
 able to comply with Rule 15c2-11(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Operations Related</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Absence of Certain Changes</u>. No event has occurred that would have a Material Adverse Effect on
 the Company or any Subsidiary that has not been disclosed in the SEC Documents, OTC Filings
 and Disclosures. Without limiting the generality of the foregoing, except as disclosed in
 the SEC Documents, OTC Filings and Disclosures, neither the Company nor any of its Subsidiaries
 has taken any of the actions set forth on <u>Schedule 3(c)(i)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Absence of Litigation</u>. Except as disclosed in the SEC Documents, there are no actions, suits,
 investigations, inquiries or proceedings pending or, to the Knowledge of the Company, threatened
 against or affecting the Company, any Subsidiary or any of their respective properties, nor
 has the Company received any written or oral notice of any such action, suit, proceeding,
 inquiry or investigation, which would have a Material Adverse Effect or would require disclosure
 under the Securities Act or the Exchange Act. No judgment, order, writ, injunction or decree
 or award has been issued by or, to the Knowledge of the Company, requested of any court,
 arbitrator or governmental agency which would have a Material Adverse Effect. Except as disclosed
 in the SEC Documents, OTC Filings and Disclosures or as set forth on <u>Schedule 3(c)(ii)</u> there has not been, and to the Knowledge of the Company, there is not pending or contemplated,
 any investigation by the SEC involving the Company, any Subsidiary or any current or former
 director or officer of the Company or any Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Patents</u>, <u>Copyrights</u>, <u>etc</u>. The Company and the Subsidiaries own or possess adequate rights
 or licenses to use all material trademarks, trade names, service marks, service mark registrations,
 service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental
 authorizations, trade secrets and rights necessary to conduct their respective businesses
 as now conducted (" <u>Intellectual Property</u> "). None of the Company's
 nor any Subsidiary's Intellectual Property rights have expired or terminated, or, by
 the terms and conditions thereof, could expire or terminate within two years from the Execution
 Date. The Company does not have any Knowledge of any infringement by the Company and/or any
 Subsidiary of any material trademark, trade name rights, patents, patent rights, copyrights,
 inventions, licenses, service names, service marks, service mark registrations, trade secret
 or other similar rights of others, or of any such development of similar or identical trade
 secrets or technical information by others, and there is no claim, action or proceeding being
 made or brought against, or to the Company's Knowledge, being threatened against, the
 Company and/or any Subsidiary regarding trademark, trade name, patents, patent rights, invention,
 copyright, license, service names, service marks, service mark registrations, trade secret
 or other infringement, which could reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Tax Status</u>. The Company and each of its Subsidiaries has made or filed all federal and material
 state and foreign income and all other material tax returns, reports and declarations required
 by any jurisdiction to which it is subject (unless and only to the extent that the Company
 and each of its Subsidiaries has set aside on its books provisions reasonably adequate for
 the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental
 assessments and charges that are material in amount, shown or determined to be due on such
 returns, reports and declarations, except those being contested in good faith and has set
 aside on its books provisions reasonably adequate for the payment of all taxes for periods
 subsequent to the periods to which such returns, reports or declarations apply. There are
 no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction,
 and the officers of the Company know of no basis for any such claim. The Company has not
 executed a waiver with respect to the statute of limitations relating to the assessment or
 collection of any foreign, federal, state or local tax. None of the Company's tax returns
 is presently being audited by any taxing authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Certain Transactions</u>. Except as set forth in the SEC Documents, OTC Filings and Disclosures,
 none of the officers or directors of the Company or any Subsidiary, and to the Knowledge
 of the Company, none of the employees of the Company or any Subsidiary is presently a party
 to any transaction with the Company or any Subsidiary (other than for services as employees,
 officers and directors), including any contract, agreement or other arrangement providing
 for the furnishing of services to or by, providing for rental of real or personal property
 to or from, or otherwise requiring payments to or from any officer, director or such employee
 or, to the Knowledge of the Company, any entity in which any officer, director, or any such
 employee has a substantial interest or is an officer, director, trustee or partner, in each
 case in excess of the lesser of (i) $120,000 or (ii) one percent of the average of the Company's
 total assets at year-end for the last two completed fiscal years, other than for (i) payment
 of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
 on behalf of the Company or any Subsidiary and (iii) other employee benefits, including stock
 option agreements under any stock option plan of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Permits; Compliance</u>. The Company and each of its Subsidiaries is in possession of all franchises,
 grants, authorizations, licenses, permits, easements, variances, exemptions, consents, certificates,
 approvals and orders necessary to own, lease and operate its properties and to carry on its
 business as it is now being conducted (collectively, the " <u>Company Permits</u> "),
 and there is no action pending or, to the Knowledge of the Company, threatened regarding
 suspension or cancellation of any of the Company Permits. Neither the Company nor any of
 its Subsidiaries is in conflict with, or in default or violation of, any of the Company Permits,
 except for any such conflicts, defaults or violations which, individually or in the aggregate,
 would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor
 any of its Subsidiaries has received any notification with respect to possible conflicts,
 defaults or violations of applicable laws, except for notices relating to possible conflicts,
 defaults or violations, which conflicts, defaults or violations would not have a Material
 Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <u>Environmental Matters.</u> The Company is in compliance with all applicable Environmental Laws in all respects
 except where the failure to comply does not have and could not reasonably be expected to
 have a Material Adverse Effect. For purposes of the foregoing: " <u>Environmental Laws</u> "
 means, collectively, the Comprehensive Environmental Response, Compensation and Liability
 Act of 1980, as amended, the Superfund Amendments and Reauthorization Act of 1986, the Resource
 Conservation and Recovery Act, the Toxic Substances Control Act, as amended, the Clean Air
 Act, as amended, the Clean Water Act, as amended, any other "Superfund" or "Superlien"
 law or any other applicable federal, state or local statute, law, ordinance, code, rule,
 regulation, order or decree regulating, relating to, or imposing liability or standards of
 conduct concerning, the environment or any Hazardous Material.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) <u>Title to Property</u>. Except as disclosed in the SEC Documents, OTC Filings and Disclosures, the
 Company and each Subsidiary has good and marketable title in fee simple to all real property
 owned by it and good and marketable title in all personal property owned by it that is material
 to the business of the Company and each Subsidiary, in each case free and clear of all Liens
 and, except for Liens as do not materially affect the value of such property and do not materially
 interfere with the use made and proposed to be made of such property by the Company or any
 Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which
 is neither delinquent nor subject to penalties. Any real property and facilities held under
 lease by the Company, or any Subsidiary is held under valid, subsisting and enforceable leases
 with which the Company is in compliance with such exceptions as are not material and do not
 interfere with the use made and proposed to be made of such property and buildings by the
 Company or any Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) <u>Internal Accounting Controls</u>. Except as disclosed in the SEC Documents the Company and each of
 its Subsidiaries maintain a system of internal accounting controls sufficient, in the judgment
 of the Company's board of directors, to provide reasonable assurance that (i) transactions
 are executed in accordance with management's general or specific authorizations, (ii)
 transactions are recorded as necessary to permit preparation of financial statements in conformity
 with generally accepted accounting principles and to maintain asset accountability, (iii)
 access to assets is permitted only in accordance with management's general or specific
 authorization and (iv) the recorded accountability for assets is compared with the existing
 assets at reasonable intervals and appropriate action is taken with respect to any differences.
 The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended,
 which are applicable to it.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>Foreign Corrupt Practices</u>. Neither the Company, nor any of its Subsidiaries, nor any director,
 officer, agent, employee or other person acting on behalf of the Company or any Subsidiary
 has, in the course of his actions for, or on behalf of, the Company, used any corporate funds
 for any unlawful contribution, gift, entertainment or other unlawful expenses relating to
 political activity; made any direct or indirect unlawful payment to any foreign or domestic
 government official or employee from corporate funds; violated or is in violation of any
 provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any bribe,
 rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic
 government official or employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) <u>Solvency</u>.
 The Company (after giving effect to the transactions contemplated by this Agreement) is solvent
 (i.e., its assets have a fair market value in excess of the amount required to pay its probable
 liabilities on its existing debts as they become absolute and matured) and currently the
 Company has no information that would lead it to reasonably conclude that the Company would
 not, after giving effect to the transaction contemplated by this Agreement, have the ability
 to, nor does it intend to take any action that would impair its ability to, pay its debts
 from time to time incurred in connection therewith as such debts mature. Except as disclosed
 in the SEC Documents, OTC Filings and Disclosures or on <u>Schedule 3(c)(xi)</u>, the Company
 did not receive a qualified opinion from its auditors with respect to its most recent fiscal
 year end and, after giving effect to the transactions contemplated by this Agreement, does
 not anticipate or know of any basis upon which its auditors might issue a qualified opinion
 in respect of its current fiscal year. For the avoidance of doubt any qualification of the
 auditors' opinion relating to the Company's ability to continue as a "going
 concern" shall not, by itself, be a violation of this <u>Section 3(c)(xi)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) <u>Insurance</u>.
 The Company and each Subsidiary is insured by insurers of recognized financial responsibility
 against such losses and risks and in such amounts as management of the Company believes to
 be prudent and customary in the businesses in which the Company and each Subsidiary is engaged.
 Neither the Company, nor any Subsidiary has been refused any insurance coverage sought or
 applied for, and the Company has no reason to believe that it or any Subsidiary will not
 be able to renew its existing insurance coverage as and when such coverage expires or to
 obtain similar coverage from similar insurers as may be necessary to continue its business
 at a cost that would not materially and adversely affect the condition, financial or otherwise,
 or the earnings, business or operations of the Company, taken as a whole.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) <u>No Undisclosed Events, Liabilities, Developments or Circumstances</u>. Except as set forth in
 the SEC Documents, OTC Filings and Disclosures, the Company and its Subsidiaries have no
 liabilities or obligations of any nature (whether accrued, absolute, contingent, unasserted
 or otherwise and whether due or to become due) other than those liabilities or obligations
 that are disclosed in the Financial Statements or which do not exceed, individually in excess
 of $50,000 and in the aggregate in excess of $200,000. The reserves, if any, established
 by the Company or the lack of reserves, if applicable, are reasonable based upon facts and
 circumstances known by the Company on the Execution Date and there are no loss contingencies
 that are required to be accrued by the Statement of Financial Accounting Standard No. 5 of
 the Financial Accounting Standards Board which are not provided for in the Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) <u>Management</u>.
 During the past five-year period, no current or former officer or director or, to the Knowledge
 of the Company, stockholder of the Company or any of its Subsidiaries has been the subject
 of any matter that would require disclosure under Paragraph (f) of Rule 401 of Regulation
 S-K that has not been publicly disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) <u>Assets; Title</u>. Except as disclosed on <u>Schedule 3(c)(xv)</u>, each of the Company and its Subsidiaries
 has good and valid title to, or a valid leasehold interest in, as applicable, all of its
 properties and assets, free and clear of all Liens except (i) any Lien for taxes not yet
 due or delinquent or being contested in good faith by appropriate proceedings for which adequate
 reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in
 the ordinary course of business by operation of law with respect to a liability that is not

 liens, mechanics' liens and other similar liens, arising in the ordinary course of
 business with respect to a liability that is not yet due or delinquent or that are being
 contested in good faith by appropriate proceedings, and (iv) such as have been disposed of
 in the ordinary course of business. To the Company's Knowledge, all tangible personal
 property owned by the Company and its Subsidiaries has been maintained in good operating
 condition and repair, except (x) for ordinary wear and tear, and (y) where such failure would
 not have a Material Adverse Effect. To the Company's Knowledge, all assets leased by
 the Company or any of its Subsidiaries are in the condition required by the terms of the
 lease applicable thereto during the term of such lease and upon the expiration thereof. To
 the Company's Knowledge, the Company and its Subsidiaries have good and marketable
 title in fee simple to all real property and good and marketable title to all personal property
 owned by them which is material to the business of the Company and its Subsidiaries, in each
 case free and clear of all liens, encumbrances and defects. Any real property and facilities
 held under lease by the Company or any of its Subsidiaries are held by them under valid,
 subsisting and enforceable leases with such exceptions as are not material and do not interfere
 with the use made and proposed to be made of such property and buildings by the Company and
 its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) <u>Subsidiary Rights</u>. The Company or one of its Subsidiaries has the unrestricted right to vote, and
 to receive dividends and distributions on, all equity securities of its Subsidiaries as owned
 by the Company or such Subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) <u>Books and Records</u>. To the Company's Knowledge, the books of account, ledgers, order books,
 records and documents of the Company and its Subsidiaries accurately and completely reflect
 all information relating to the respective businesses of the Company and its Subsidiaries,
 the nature, acquisition, maintenance, location and collection of each of their respective
 assets, and the nature of all transactions giving rise to material obligations or accounts
 receivable of the Company or its Subsidiaries, as the case may be, except where the failure
 to so reflect such information would not have a Material Adverse Effect. To the Company's
 Knowledge, the minute books of the Company and its Subsidiaries contain accurate records
 in all material respects of all meetings and accurately reflect all other actions taken by
 the stockholders, boards of directors and all committees of the boards of directors, and
 other governing Persons of the Company and its Subsidiaries, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii) <u>Money Laundering</u>. The Company and its Subsidiaries are in compliance with, and have not previously
 violated, the USA PATRIOT ACT of 2001 and all other applicable U.S. and non-U.S. anti-money
 laundering laws and regulations, including, but not limited to, the laws, regulations and
 Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets
 Control, including, but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled,
 "Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to
 Commit, or Support Terrorism" (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
 contained in 31 CFR, Subtitle B, Chapter V.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>General</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Acknowledgment of Dilution</u>. The Company understands and acknowledges the potentially dilutive effect
 to the Common Stock upon the issuance of the Conversion Shares upon conversion of the Note.
 The Company further acknowledges that its obligation to issue Conversion Shares upon conversion
 of the Note is absolute and unconditional regardless of the dilutive effect that such issuances
 may have on the ownership interests of other stockholders of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Breach of Representations and Warranties by the Company</u>. If the Company breaches any of the
 representations or warranties set forth in this <u>Section 3</u>, and in addition to any
 other remedies available to the Buyer pursuant to this Agreement, it will be considered an
 Event of Default under the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Absence of Schedules</u>. In the event that at the Closing Date, the Company does not deliver and
 attach hereto any disclosure schedule contemplated by this Agreement, the Company hereby
 acknowledges and agrees that (i) each such undelivered disclosure schedule shall be deemed
 to read as follows: "Nothing to Disclose", and (ii) the Buyer has not otherwise
 waived delivery of such disclosure schedule.

4. <u>GENERAL COVENANTS.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Best Efforts</u>. The parties shall use their commercially reasonable best efforts to satisfy
 timely each of the conditions described in <u>Section 7</u> and <u>8</u> of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Use of Proceeds</u>. The Company shall use the proceeds from the sale of the Notes first as set
 forth on <u>Schedule 4(b)</u>, and thereafter for other general corporate purposes and shall
 not, directly or indirectly, use such proceeds for any loan to or investment in any other
 corporation, partnership, enterprise or other person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Financial Information</u>. The Company agrees to send or make available the following reports to the
 Buyer until the Buyer transfers, assigns, or sells all of the Securities: (i) within ten
 (10) days after the filing with the SEC, a copy of its Annual Report on Form 10-K, its Quarterly
 Reports on Form 10-Q and any Current Reports on Form 8-K; (ii) within five (5) days after
 upload or filing, any filings made in the SEC Documents, OTC Filings and Disclosures; (iii)
 within one (1) day after release, copies of all press releases issued by the Company or any
 of its Subsidiaries relating to the transactions contemplated hereby; and (iv) contemporaneously
 with the making available or giving to the stockholders of the Company, copies of any notices
 or other information the Company makes available or gives to such stockholders. For the avoidance
 of doubt, filing the documents required in (i) above via EDGAR or releasing any documents
 set forth in (ii) above via a recognized wire service shall satisfy the delivery requirements
 of this <u>Section 4(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Listing</u>.
 The Company shall work in good faith to secure the listing of the Conversion Shares upon
 each national securities exchange or automated quotation system, if any, upon which shares
 of Common Stock are then listed (subject to official notice of issuance) and, so long as
 the Buyer owns any of the Securities, shall maintain, so long as any other shares of Common
 Stock shall be so listed, such listing of all Conversion Shares from time to time issuable
 upon exercise of the Note. The Company will obtain and, so long as the Buyer owns any of
 the Securities, maintain the listing and trading of its Common Stock on the Trading Market
 and will comply in all respects with the Company's reporting, filing and other obligations
 under the bylaws or rules of the Financial Industry Regulatory Authority (" <u>FINRA</u> ")
 and such exchanges, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Corporate Existence</u>. So long as the Buyer beneficially owns any of the Securities, the Company
 shall maintain its corporate existence and shall not sell all or substantially all of the
 Company's assets, except in the event of a merger or consolidation or sale of all or
 substantially all of the Company's assets, where the surviving or successor entity
 in such transaction (i) assumes the Company's obligations hereunder and under the agreements
 and instruments entered into in connection herewith and (ii) is a publicly traded corporation
 whose Common Stock is listed or quoted for trading on the Trading Market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>No Integration</u>. The Company shall not make any offers or sales of any security (other than
 the Securities) under circumstances that would require registration of the Securities being
 offered or sold hereunder under the Securities Act or cause the offering of the Securities
 to be integrated with any other offering of securities by the Company for the purpose of
 any stockholder approval provision applicable to the Company or its securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Failure to Comply with the Exchange Act</u>. So long as the Buyer beneficially owns any of the Securities,
 the Company shall comply with the reporting requirements of the Exchange Act; and the Company
 be subject to the periodic reporting and other reporting requirements of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Breach of Covenants</u>. If the Company breaches any of the covenants set forth in this <u>Section 4</u>, then in addition to any other remedies available to the Buyer pursuant to this Agreement,
 each such breach will be considered an "Event of Default" under the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Reservation of Shares</u>. The Company covenants that while the Note remains outstanding, the Company
 will reserve from its authorized and unissued Common Stock, three times (300%) of the number
 of shares of Common Stock, free from pre-emptive rights, that would be issuable upon full,
 unconditioned conversion of the Note calculated on the basis of the conversion price, in
 effect as the Closing Date, which such reserved amounts shall be increased by the Company
 from time to time in accordance with its obligations under such Securities. In addition to
 all other rights in this Agreement and the Note, in the event that on any date (the " <u>Reserve Depletion Date</u> ") the Company does not have available enough authorized shares of
 Common Stock to satisfy any conversion request regarding the Note, the Company shall repay
 all outstanding amounts owed under the Note in full within sixty (60) days of the Reserve
 Depletion Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Indemnification</u>.
 Each party hereto (an " <u>Indemnifying Party</u> ") agrees to indemnify and hold
 harmless the other party along with its officers, directors, employees, and authorized agents,
 and each Person or entity, if any, who controls such party within the meaning of Section
 15 of the Securities Act or Section 20 of the Exchange Act or the rules and regulations thereunder
 (an " <u>Indemnified Party</u> ") from and against any Damages, joint or several,
 and any action in respect thereof to which the Indemnified Party becomes subject to, resulting
 from, arising out of or relating to any misrepresentation, breach of warranty or nonfulfillment
 of or failure to perform any covenant or agreement on the part of the Indemnifying Party
 contained in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Certain Expenses and Fees</u>. The Company shall pay all stamp taxes and other taxes and duties levied
 in connection with the delivery of the Note to the Buyer. In addition, the Buyer shall be
 entitled to withhold $3,500.00 for the Buyer's legal fees from the amounts delivered
 at Closing, such amounts to be paid directly to the Buyer's counsel.

5. <u>SPECIAL COVENANTS</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Piggyback Registration Rights</u>. The Company shall include on any registration and/or offering statement
 filed with the SEC, including without limitation on any offering statement on Form 1-A, all
 Conversion Shares, for resale by the Buyer. In addition to all other remedies at law or in
 equity or otherwise under this Agreement or other Transaction Documents, failure to do so
 will result in liquidated damages of $20,000.00 pursuant to this <u>Section 5(a)</u>, being
 immediately due and payable to the Buyer at its election in the form of cash payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Variable Rate Transactions</u>. [RESERVED].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Up-listing.</u> [RESERVED].

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Participation Rights</u>. During the twelve (12) months immediately following the Closing, with respect
 to each and any securities offering conducted by the Company, the Company agrees to, and
 hereby does, irrevocably grant to the Buyer the option to purchase securities offered in
 such offering at the applicable offering prices thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Repayment from Proceeds</u>. [RESERVED]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Right of First Refusal</u>. During the nine (9) months immediately following the Closing, in the
 event that the Company receives a Bona Fide Offer (defined below) of capital or financing
 from any third party consisting of any securities offering, including but not limited to
 any debt or equity securities, then the Company must, and irrevocably agrees to, first offer
 such opportunity to the Buyer to provide such capital or financing to the Company on the
 same or similar terms as each respective third party's terms, and the Buyer may in
 its sole discretion determine whether the Buyer will provide such capital or financing. Upon
 receipt of the third-party offer, the Company shall promptly provide notice thereof to the
 Buyer (the " <u>Offer Notice</u> ") and provide copies of the pending transaction
 documents. Should the Buyer be unwilling or unable to provide such capital or financing to
 the Company within two (2) Trading Days from the Buyer's receipt of the Offer Notice
 from the Company, then the Company may obtain such capital or financing from the respective
 third party upon the exact same terms and conditions offered by the Company to the Buyer,
 which transaction must be completed within seven (7) Trading Days after the date of the Offer
 Notice. If the Company does not receive the capital or financing from the respective third
 party within seven (7) Trading Days after the date of the respective Offer Notice, then the
 Company must again offer the capital or financing opportunity to the Buyer as described above,
 and the process detailed above shall be repeated. A " <u>Bona Fide Offer</u> "
 is one in which the purchaser is irrevocably and contractually bound to purchase the subject
 securities from the Company, subject to the Buyer's right of first refusal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Compliance with Rule 15c2-11</u>. The Company take all actions to maintain as publicly available all
 information required by paragraph (b) of Rule 15c2-11 of the Exchange Act (as effective on
 September 26, 2021), as amended, such that brokers or dealers attempting to publish any quotation
 for the Common Stock or, directly or indirectly, to submit any such quotation for publication,
 shall be able to comply with Rule 15c2-11(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Prohibition on Certain Transactions</u>. The Buyer covenants and agrees that neither it nor any affiliate
 acting on its behalf or pursuant to any understanding with it will execute any "short
 sales" of the Common Stock as defined in Rule 200 of Regulation SHO under the Exchange
 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Most Favoured Nation</u>. While the Note or any principal amount, interest or fees or expenses
 due thereunder remain outstanding and unpaid, the Company shall not enter into any public
 or private offering of its securities (including securities convertible into shares of Common
 Stock) with any individual or entity (an "Other Investor") that has the effect
 of establishing rights or otherwise benefiting such Other Investor in a manner more favourable
 in any material respect to such Other Investor than the rights and benefits established in
 favor of the Buyer by this Agreement or the Note unless, in any such case, the Buyer has
 been provided with such rights and benefits pursuant to a definitive written agreement or
 agreements between the Company and the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Audit</u>.
 The Company shall maintain an engagement with a PCAOB registered accounting firm at all times
 the Securities are outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Breach of Covenants</u>. If the Company breaches any of the covenants set forth in this <u>Section 5</u>, then in addition to any other remedies available to the Buyer pursuant to this Agreement,
 each such breach will be considered an "Event of Default" under the Note.

6. <u>Transfer Agent Instructions</u>.
 Prior to registration of the Conversion Shares under the Securities Act or the date on which
 the Conversion Shares may be sold pursuant to Rule 144 without any restriction as to the
 number of Securities as of a particular date that can then be immediately sold, all such
 certificates shall bear the restrictive legend specified in the Note. The Company warrants
 that: (i) no stop transfer instructions will be given by the Company to its Transfer Agent
 and that the Securities shall otherwise be freely transferable on the books and records of
 the Company as and to the extent provided in this Agreement and the Note; (ii) it will not
 direct its Transfer Agent not to transfer or delay, impair, and/or hinder its Transfer Agent
 in transferring (or issuing) (electronically or in certificated form) any certificate for
 Conversion Shares to be issued to the Buyer upon conversion of or otherwise pursuant to the
 Note, as and when required by the Note or this Agreement; and (iii) it will not fail to remove
 (or direct its Transfer Agent not to remove or impairs, delays, and/or hinders its Transfer
 Agent from removing) any restrictive legend (or to withdraw any stop transfer instructions
 in respect thereof) on any certificate for any Conversion Shares as contemplated by the terms
 of this Agreement and the Note, as applicable. Nothing in this Section shall affect in any
 way the Buyer's obligations and agreement to comply with all applicable prospectus
 delivery requirements, if any, upon re-sale of the Securities. If the Buyer provides the
 Company (which shall be at the cost of the Company), with (i) an opinion of counsel in form,
 substance and scope customary for opinions in comparable transactions, to the effect that
 a public sale or transfer of any Securities may be made without registration under the Securities
 Act and such sale or transfer is effected or (ii) the Buyer provides reasonable assurances
 that the Securities can be sold pursuant to Rule 144, the Company shall permit the transfer,
 and, in the case of the Conversion Shares, promptly instruct its Transfer Agent to issue
 one or more certificates, free from restrictive legend, in such name and in such denominations
 as specified by the Buyer or, in the sole discretion of the Buyer, the Company shall take
 all action necessary to ensure that such Common Stock is transferred electronically as DWAC
 (as defined in the Note) shares. The Company acknowledges that a breach by it of its obligations
 hereunder will cause irreparable harm to the Buyer, by vitiating the intent and purpose of
 the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy
 at law for a breach of its obligations under this Section may be inadequate and agrees, in
 the event of a breach or threatened breach by the Company of the provisions of this Section,
 that the Buyer shall be entitled, in addition to all other available remedies, to an injunction
 restraining any breach and requiring immediate transfer, without the necessity of showing
 economic loss and without any bond or other security being required.

7. <u>CONDITIONS PRECEDENT TO THE COMPANY'S OBLIGATIONS TO SELL</u>. The obligation of the Company hereunder
 to issue and sell any Note, to the Buyer at the Closing is subject to the satisfaction, at
 or before the Closing Date of each of the following conditions thereto, provided that these
 conditions are for the Company's sole benefit and may be waived by the Company at any
 time in its sole discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Buyer shall have executed this Agreement and delivered the same to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The
 Buyer shall have delivered the Company Funding Amount in accordance with <u>Section 1</u> above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The
 representations and warranties of the Buyer shall be true and correct in all material respects
 as of the date when made and as of the Closing Date as though made at that time (except for
 representations and warranties that speak as of a specific date), and the Buyer shall have
 performed, satisfied and complied in all material respects with the covenants, agreements,
 and conditions required by this Agreement to be performed, satisfied or complied with by
 the Buyer at or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No
 litigation, statute, rule, regulation, executive order, decree, ruling, or injunction shall
 have been enacted, entered, promulgated, or endorsed by or in any court or governmental authority
 of competent jurisdiction or any self-regulatory organization having authority over the matters
 contemplated hereby which prohibits the consummation of any of the transactions contemplated
 by this Agreement.

8. <u>CONDITIONS PRECEDENT TO THE BUYER'S OBLIGATION TO PURCHASE</u>. The obligation of the Buyer hereunder
 to purchase the Note and fund such Note at the Closing is subject to the satisfaction, at
 or before the Closing Date of each of the following conditions, provided that these conditions
 are for the Buyer's sole benefit and may be waived by the Buyer at any time in its
 sole discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Company shall have executed this Agreement and delivered the same to the Buyer on the Closing
 Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The
 Company shall have delivered to the Buyer the duly executed Note in accordance with <u>Section 1</u> above on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The
 Company shall have delivered to the Buyer the duly executed Transfer Agent Instruction Letter
 on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The
 Company shall have delivered a copy of its Directors' resolutions relating to the transactions <u>Exhibit C</u> contemplated hereby, the form of which is attached hereto as, on the Closing
 Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) No
 litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall
 have been enacted, entered, promulgated or endorsed by or in any court or governmental authority
 of competent jurisdiction or any self-regulatory organization having authority over the matters
 contemplated hereby which prohibits the consummation of any of the transactions contemplated
 by this Agreement, as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) No
 event shall have occurred which could reasonably be expected to have a Material Adverse Effect
 on the Company including but not limited to a change in the Exchange Act reporting status
 of the Company or the failure of the Company to be timely in its Exchange Act reporting obligations,
 as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The
 representations and warranties of the Company shall be true and correct in all material respects
 as of the date when made and as of the Execution Date and the Closing Date as though made
 at such time (except for representations and warranties that speak as of a specific date,
 which shall be true and correct in all material respects as of such specific date) and the
 Company shall have performed, satisfied and complied in all material respects with the covenants,
 agreements and conditions required by this Agreement to be performed, satisfied or complied
 with by the Company at or prior to the Closing Date. The Buyer shall have received a certificate
 or certificates, executed by the chief executive officer of the Company, dated as of the
 Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested
 by the Buyer, in the form prescribed by the Buyer.

9. <u>GOVERNING LAW; MISCELLANEOUS</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of
 the State of Nevada without regard to principles of conflicts of laws. Any action brought
 by either party against the other concerning the transactions contemplated by this Agreement
 shall be brought only in the state courts of Miami, Florida, or in the federal courts located
 in the Southern District of Florida. The parties to this Agreement hereby irrevocably waive
 any objection to jurisdiction and venue of any action instituted hereunder and shall not
 assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.
 The prevailing party shall be entitled to recover from the other party its reasonable attorney's
 fees and costs. In the event that any provision of this Agreement or any other agreement
 delivered in connection herewith is invalid or unenforceable under any applicable statute
 or rule of law, then such provision shall be deemed inoperative to the extent that it may
 conflict therewith and shall be deemed modified to conform with such statute or rule of law.
 Any such provision which may prove invalid or unenforceable under any law shall not affect
 the validity or enforceability of any other provision of any agreement. Each party hereby
 irrevocably waives personal service of process and consents to process being served in any
 suit, action or proceeding in connection with this Agreement or any other Transaction Document
 by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
 of delivery) to such party at the address in effect for notices to it under this Agreement
 and agrees that such service shall constitute good and sufficient service of process and
 notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
 serve process in any other manner permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)**  **<u>JURY TRIAL WAIVER</u>. THE COMPANY AND THE BUYER HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THE TRANSACTION DOCUMENTS.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Counterparts; Signatures by Electronic Mail</u>. This Agreement may be executed in one or more counterparts,
 each of which shall be deemed an original but all of which shall constitute one and the same
 agreement and shall become effective when counterparts have been signed by each party and
 delivered to the other party. This Agreement, once executed by a party, may be delivered
 to the other party hereto by electronic mail transmission of a copy of this Agreement bearing
 the signature of the party so delivering this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Headings</u>.
 The headings of this Agreement are for the convenience of reference only and shall not form
 part of, or affect the interpretation of, this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Severability</u>.
 In the event that any provision of this Agreement or of any of the Transaction Documents
 is invalid or unenforceable under any applicable statute or rule of law, then such provision
 shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
 modified to conform with such statute or rule of law. Any provision hereof which may prove
 invalid or unenforceable under any law shall not affect the validity or enforceability of
 any other provision hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Entire Agreement; Amendments</u>. This Agreement and the instruments referenced herein contain the
 entire understanding of the parties with respect to the matters covered herein and therein
 and, except as specifically set forth herein or therein, neither the Company nor the Buyer
 makes any representation, warranty, covenant or undertaking with respect to such matters.
 No provision of this Agreement may be waived or amended other than by an instrument in writing
 signed by the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Notices</u>.
 All notices, demands, requests, consents, approvals, and other communications required or
 permitted hereunder shall be in writing and, unless otherwise specified herein, shall be
 (a) personally served, (b) deposited in the mail, registered or certified, return receipt
 requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid,
 or (d) transmitted by hand delivery, or e-mail as a PDF (with read receipt), addressed as
 set forth below or to such other address as such party shall have specified most recently
 by written notice given in accordance herewith. Any notice or other communication required
 or permitted to be given hereunder shall be deemed effective (i) upon hand delivery or delivery
 by e-mail (with read receipt) at the address designated below (if delivered on a business
 day during normal business hours where such notice is to be received), or the first business
 day following such delivery (if delivered other than on a business day during normal business
 hours where such notice is to be received) or (ii) on the second business day following the
 date of mailing by express courier service or on the fifth business day after deposited in
 the mail, in each case, fully prepaid, addressed to such address, or upon actual receipt
 of such mailing, whichever shall first occur.

If to the Company, to:

**SIGYN THERAPEUTICS, INC.**

2205 Historic Decatur Road

Suite 140

San Diego, CA 92106

Attn: James Allen Joyce, CEO

If to the Buyer, to:

**LAMBDA VENTURE PARTNERS, LLC**

6586 Hypoluxo Road #106

Lake Worth, FL 33467

Attn: Andrew Avitan, Manager

Either party hereto may from time to time change its address or e-mail for notices under this <u>Section 9(g)</u> by giving at least ten (10) days' prior written notice of such changed address to the other party hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties
 and their successors and assigns. Neither the Company nor the Buyer shall assign this Agreement
 or any rights or obligations hereunder without the prior written consent of the other. Notwithstanding
 the foregoing, subject to <u>Section 2(e)</u>, the Buyer may assign its rights hereunder
 to any person that purchases Securities in a private transaction from the Buyer or to any
 of its "affiliates," as that term is defined under the Exchange Act, without
 the consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Third Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto
 and their respective permitted successors and assigns and is not for the benefit of, nor
 may any provision hereof be enforced by, any other person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Survival</u>.
 The representations and warranties of the Company and the agreements and covenants set forth
 in this Agreement shall survive the Closings hereunder as well as the termination/satisfaction
 of the Note for the longest period allowable under applicable law. The Company agrees to
 indemnify and hold harmless the Buyer and all their officers, directors, employees and agents
 for loss or damage arising as a result of or related to any breach by the Company of any
 of its representations, warranties and covenants set forth in this Agreement or any of its
 covenants and obligations under this Agreement, including advancement of expenses as they
 are incurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Further Assurances</u>. Each party shall do and perform, or cause to be done and performed, all such
 further acts and things, and shall execute and deliver all such other agreements, certificates,
 instruments and documents, as the other party may reasonably request in order to carry out
 the intent and accomplish the purposes of this Agreement and the consummation of the transactions
 contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>No Strict Construction</u>. The language used in this Agreement will be deemed to be the language
 chosen by the parties to express their mutual intent, and no rules of strict construction
 will be applied against any party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Remedies</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The
 Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
 harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby.
 Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations
 under this Agreement will be inadequate and agrees, in the event of a breach or threatened
 breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled,
 in addition to all other available remedies at law or in equity, and in addition to the penalties
 assessable herein, to an injunction or injunctions restraining, preventing or curing any
 breach of this Agreement and to enforce specifically the terms and provisions hereof, without
 the necessity of showing economic loss and without any bond or other security being required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In
 addition to any other remedy provided herein or in any document executed in connection herewith,
 the Company shall pay the Buyer for all costs, fees and expenses in connection with any arbitration,
 litigation, contest, dispute, suit or any other action to enforce any rights of the Buyer
 against the Company in connection herewith, including, but not limited to, costs and expenses
 and attorneys' fees, and costs and time charges of counsel to the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Publicity</u>.
 The Company and the Buyer shall have the right to review a reasonable period of time before
 issuance of any press releases, SEC, Trading Market, or FINRA filings, or any other public
 statements with respect to the transactions contemplated hereby; <u>provided</u>, <u>however</u>,
 that the Company shall be entitled, without the prior approval of the Buyer, to make any
 press release or SEC, Trading Market or FINRA filings with respect to such transactions as
 is required by applicable law and regulations (although the Buyer shall be consulted by the
 Company in connection with any such press release prior to its release and shall be provided
 with a copy thereof).

10. <u>DEFINED TERMS</u>. As used in this Agreement, the following terms shall have the following meanings
 specified or indicated (such meanings to be equally applicable to both the singular and plural
 forms of the terms defined):

"<u>Affiliate</u>" means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such Person, and the term "control" (including the terms "controlled by" and "under common control with") means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such Person, whether through ownership of voting securities, by contract or otherwise.

"<u>Common Stock Equivalents</u>" means any securities of the Company or the Subsidiaries that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

"<u>Damages</u>" shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys' fees and disbursements and costs and expenses of expert witnesses and investigation).

"<u>Exchange Act</u>" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"<u>Hazardous Material</u>" means and includes any hazardous, toxic or dangerous waste, substance or material, the generation, handling, storage, disposal, treatment or emission of which is subject to any Environmental Law.

"<u>Knowledge</u>" including the phrase "<u>to the Company's Knowledge</u>" shall mean the actual knowledge after reasonable investigation of the Company's officers and directors.

"<u>Lien</u>" means a lien, charge, pledge, security interest, encumbrance, right of first refusal, pre-emptive right or any other restriction.

"<u>Material Adverse Effect</u>" means any effect on the business, operations, properties, or financial condition of the Company and/or the Subsidiaries that is material and adverse to the Company and/or the Subsidiaries and/or any condition, circumstance, or situation that prohibits or otherwise materially interferes with the ability of the Company and/or the Subsidiaries to enter into and/or perform its obligations under any Transaction Document.

"<u>OTC Filings and Disclosures</u>" shall mean the Company's documents uploaded as of the Execution Date onto the Company's "Filings and Disclosures" page on the OTCMarkets.com website.

"<u>Person</u>" means an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

"<u>Registrable Securities</u>" means all of the Conversion Shares, and any and all shares of capital stock issued or issuable as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, without regard to any limitation on issuances under any of the Transaction Documents.

"<u>Securities</u>" means, collectively, the Note, the Conversion Shares, and any other securities of the Company issued in connection with or in exchange for any of the foregoing.

"<u>Subsidiary</u>" or "<u>Subsidiaries</u>" means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.

"<u>Trading Day</u>" shall mean a day on which the NASDAQ stock market shall be open for business.

"<u>Trading Market</u>" means the OTC-PINK market of the OTC-Markets.

"<u>Transaction Documents</u>" shall mean this Agreement, the Note, the Transfer Agent Instruction Letter and all schedules and exhibits hereto and thereto.

"<u>Transfer Agent</u>" shall mean the current transfer agent of the Company, and any successor transfer agent of the Company.

"<u>Transfer Agent Instruction Letter</u>" means the letter from the Company to the Transfer Agent in the form of <u>Exhibit C</u> attached hereto.

**IN WITNESS WHEREOF,** the Buyer and the Company have caused their respective signature page to this Note Purchase Agreement to be duly executed as of the Execution Date.

---

| | |
|:---|:---|
| **<u>COMPANY</u>:** | **<u>COMPANY</u>:** |
| **SIGYN THERAPEUTICS, INC.** | **SIGYN THERAPEUTICS, INC.** |
| By: |  |
| Name: | James Allen Joyce |
| Title: | CEO |
| **<u>BUYER</u>:** | **<u>BUYER</u>:** |
| **LAMBDA VENTURE PARTNERS, LLC** | **LAMBDA VENTURE PARTNERS, LLC** |
| By: |  |
| Name: | Andrew Avitan |
| Title: | Manager |

---

**<u>ISSUANCE SCHEDULE</u>**

---

| | | |
|:---|:---|:---|
| **(1)** | **(2)** | **(3)** |
| **Buyer** | **Face Value of Note** | **Funding Amount** |
| Lambda Venture Partners, LLC | $110000 \* | $103500 |

---

\* The first closing of the Note shall result in the purchase of $110,000 under the Note for a purchase price of $103,500 with a $3,500 deduction in legal fees resulting in net proceeds to the Company of $100,000

**<u>DISCLOSURE SCHEDULES</u>**

**<u>Schedule 3(c)(i)</u>**

Except as disclosed in the SEC Documents, OTC Filings, and Disclosures, neither the Company nor any of its Subsidiaries has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) declared, set aside, or paid any dividend or other distribution with respect to any shares of capital stock of the Company or any of its Subsidiaries or any direct or indirect redemption, purchase or other acquisition of any such shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) sold, assigned, pledged, encumbered, transferred or otherwise disposed of any tangible asset of the Company or any of its Subsidiaries (other than sales or the licensing of its products to customers in the ordinary course of business consistent with past practice), or sold, assigned, pledged, encumbered, transferred or otherwise disposed of any Intellectual Property (as defined below), other than licensing of products of the Company or its Subsidiaries in the ordinary course of business and on a non-exclusive basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) entered into any licensing or other agreement with regard to the acquisition or disposition of any Intellectual Property other than licenses in the ordinary course of business consistent with past practice or any amendment or consent with respect to any licensing agreement filed or required to be filed with respect to any governmental authority;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) made capital expenditures, individually or in the aggregate, in excess of $100,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) incurred any obligation or liability (whether absolute, accrued, contingent or otherwise, and whether due or to become due) on the Company's behalf or any of its Subsidiaries, in excess of $100,000 individually, other than obligations under customer contracts, current obligations and liabilities, in each case incurred in the ordinary course of business and consistent with past practice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) had any Lien on any property of the Company or any of its Subsidiaries except as disclosed in the SEC Documents, OTC Filings and Disclosures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) made any payment, discharge, satisfaction or settlement of any suit, action, claim, arbitration, proceeding or obligation of the Company or any of its Subsidiaries, except in the ordinary course of business and consistent with past practice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) effected any split, combination or reclassification of any equity securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) sustained any material loss, destruction or damage to any property of the Company or any Subsidiary, whether or not insured;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) effected any acceleration or prepayment of any indebtedness for borrowed money or the refunding of any such indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11) experienced any labor trouble involving the Company or any Subsidiary or any material change in their personnel or the terms and conditions of employment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12) made any waiver of any valuable right, whether by contract or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) made any loan or extension of credit to any officer or employee of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(14) made any change in the independent public accountants of the Company or its Subsidiaries or any material change in the accounting methods or accounting practices followed by the Company or its Subsidiaries, as applicable, or any material change in depreciation or amortization policies or rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) experienced any resignation or termination of any officer, key employee or group of employees of the Company or any of its Subsidiaries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16) effected any change in any compensation arrangement or agreement with any employee, officer, director or stockholder that would result in the aggregate compensation to such Person in such year to exceed $100,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) effected any material increase in the compensation of employees of the Company or its Subsidiaries (including any increase pursuant to any written bonus, pension, profit sharing or other benefit or compensation plan, policy or arrangement or commitment), or any increase in any such compensation or bonus payable to any officer, stockholder, director, consultant or agent of the Company or any of its Subsidiaries having an annual salary or remuneration in excess of $100,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) made any revaluation of any of their respective assets, including, without limitation, writing down the value of capitalized inventory or writing off notes or accounts receivable or any sale of assets other than in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) made any acquisition or disposition of any material assets (or any contract or arrangement therefore), or any other material transaction by the Company or any Subsidiary otherwise than for fair value in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(20) written-down the value of any asset of the Company or its Subsidiaries or written-off as uncollectible of any accounts or notes receivable or any portion thereof except in the ordinary course of business and in a magnitude consistent with historical practice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) cancelled any debts or claims or any material amendment, termination or waiver of any rights of the Company or its Subsidiaries; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(22) entered into any agreement, whether in writing or otherwise, to take any of the actions specified in the foregoing items <u>(1)</u> through (<u>21</u>).

**<u>SCHEDULE 4(b)</u>**

**Use of Proceeds**

(1) General working capital.

**<u>EXHIBITS</u>**

**<u>A - NOTE</u>**

**<u>B - TRANSFER AGENT INSTRUCTIONS</u>**

**<u>C - BOARD RESOLUTIONS</u>**